[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509575":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":33,"collaborators":7,"id":36,"slug":7,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":7,"eligibilityCriteria":40,"healthyVolunteers":37,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":56,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Gaurav Goyal, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","1-866-438-1640","histio@uabmc.edu",[18],{"facility":5,"status":19,"city":20,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":26,"coordinates":27},"Point",[28,29],-86.80249,33.52066,{"lat":29,"lon":28},[32],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"type":11,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Gaurav Goyal","Principal Investigator","100509575",false,"NCT05915208","Histiocytic Disorder Follow-up Study","Inclusion Criteria:\n\n* diagnosis of histiocytic disorder at any age\n\n  1. Langerhans cell histiocytosis,\n  2. Erdheim-Chester disease,\n  3. Rosai-Dorfman disease,\n  4. Xanthogranuloma,\n  5. Mixed histiocytosis\n  6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)\n  7. Hemophagocytic lymphohistiocytosis\n\nExclusion Criteria:\n\n* None","ALL","0 Years","89 Years",{"count":45,"type":46},6000,"ESTIMATED","OBSERVATIONAL","The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders",[50,51,52,53,54,55],"Histiocytosis","Langerhans Cell Histiocytosis","Erdheim-Chester Disease","Rosai Dorfman Disease","Xanthogranuloma","Malignant Histiocytoses",[57,58,59,60],"survivorship","long-term","targeted therapy","second cancer","2026-06-10",{"date":63,"type":64},"2026-06-12","ACTUAL",{"date":66,"type":64},"2022-09-01",{"date":68,"type":46},"2028-12",{"name":5,"class":6},1]